A fast-track anaemia clinic in the Emergency Department: Feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia

Blood Transfusion

Volumn 14, Issue 2, 2016, Pages 126-133

  Quintana Díaz, Manuel ^a   Fabra Cadenas, Sara ^a   Gómez Ramírez, Susana ^b   Martínez Virto, Ana ^a   García Erce, José A ^a,c   Muñoz, Manuel ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD DE MÁLAGA   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

Author keywords

Fast track anaemia clinic; Hospital emergency department; Intravenous iron; Sub acute anaemia; Transfusion

Indexed keywords

FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON;

ADULT; AGED; ARTICLE; BLOOD; BRONCHOSPASM; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMERGENCY WARD; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; FOLIC ACID DEFICIENCY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERNICIOUS ANEMIA; PHLEBITIS; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; UTERUS BLEEDING; ANEMIA, IRON-DEFICIENCY; HOSPITAL EMERGENCY SERVICE; INTRAVENOUS DRUG ADMINISTRATION; RETROSPECTIVE STUDY; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRON; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84961639733     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0176-15     Document Type: Article

References (35)

1. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123: 615-24.
2. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. The prevalence of anemia in persons aged 65 and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-8.
3. Gaskell H, Derry S, Andrew Moore R, McQuay HJ. Prevalence of anaemia in older persons: systematic review. BMC Geriatr 2008; 8: 1.
4. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396-407.
5. Muñoz M, Gómez-Ramírez S, Cobos A, Enguix A. Prevalence and severity of anaemia among medical patients from different hospital departments. Transfus Altern Transfus Med 2011; 12: 30.
6. Hogshire L, Carson JL. Red blood cell transfusion: what is the evidence when to transfuse? Curr Opin Hematol 2013; 20: 546-51.
7. Allameddine A, Heaton M, Jenkins H, et al. Inappropriate use of blood transfusion in emergency department in a tertiary care hospital and potential saving with patient blood management. Transfus Med 2014; 24 (Suppl 1): 25.
8. Tirado-Anglés G, Gangutia-Hernández S, Rodríguez-Chacón L, et al. Influence of a transfusion pocket guide on physicians' transfusion practices, 2010-2013. Transfus Med 2014; 24 (Suppl 1): 27.
9. Evstatiev R, Marteau P, Iqbal T, et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.e1-2.
10. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1. Available at: http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed on 20/06/2015.
11. Keating GM Ferric carboxymaltose: a review of its use in iron deficiency. Drugs 2015; 75: 101-27.
12. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol 2014; 5: 48-60.
13. Muñoz M, Martín-Montañez E. Ferric carboxymaltose for the treatment of iron-deficiency anemia [corrected]. Expert Opin Pharmacother 2012; 13: 907-21.
14. Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. Br J Anaesth 2015; 115: 15-24.
15. Cancellere N, Fabra S, Martinez-Virto AM, et al. Evaluation of an educational intervention in transfusion medicine for medical students and postgraduate trainees. Transfus Med 2015; 25 (Suppl 1): 26.
16. Quintana M, Borobia AM, Medrano M, et al. Impact of an educational intervention on red blood cell transfusion practice. Transfus Med 2014; 24 (Suppl. 1): 27-8.
17. Abraham I, Sun D. The cost of blood transfusion in Western Europe as estimated from six studies. Transfusion 2012; 52: 1983-8.
18. Calvet X, Ruíz MÀ, Dosal A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One 2012; 7: e45604.
19. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011; 7: 103-13.
20. Beguin Y, Jaspers A. Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. Expert Opin Pharmacother 2014; 15: 2087-103.
21. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M; Anaemia Working Group España. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011; 107: 477-8.
22. Wilson PD, Hutchings A, Jeans A, Macdougall IC. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J Med Econ 2013; 16: 108-14.
23. Reinisch W, Staun M, Bhandari S, Muñoz M. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J Crohns Colitis 2013; 7: 429-40.
24. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/newsdetail-001833.jsp&mid=WC0b01ac058004d5c1. Accessed on 20/06/2015.
25. Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica 2015; 100: e214-5.
26. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12: 296-300.
27. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.
28. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99: 1671-6.
29. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One 2012; 7: e34520.
30. Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87: 308-10.
31. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015; 2015: 468675.
32. Sánchez González R, Ternavasio-de la Vega HG, Moralejo Alonso L, et al. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect.] Med Clin (Barc) 2015; 145: 108-11. [In Spanish.]
33. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014; 72: 49-53.
34. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the drug safety and risk management advisory committee, February 1, 2008. Available at: http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4337m1-Final.pdf. Accessed on 20/06/2015.
35. th ed. Sociedad Española de Transfusión Sanguínea y Terapia Celular: Barcelona; 2010. p. 43-53.